索非布韦联合达卡他韦治疗慢性丙型肝炎的临床观察

Clinical observation of sofosbuvir and daclatasvir for chronic hepatitis C

目的观察索非布韦(SOF)联合达卡他韦(DCV)治疗慢性丙型肝炎的治疗效果。方法 100例慢性丙型肝炎患者随机分为SD组(40例)和PR组(60例)。SD组采用SOF联合DCV治疗,PR组采用聚乙二醇干扰素联合利巴韦林治疗。观察并比较两组治疗后肝功能、HCV-RNA转阴率、病毒学应答率及不良反应等指标。结果与治疗4周比较,治疗48周后两组的丙氨酸转氨酶、门冬氨酸转氨酶及总胆红素异常发生率明显降低,且以SD组更为显著(P<0.05);治疗12周,SD组非Ⅰ型HCV-RNA转阴率高于PR组(P<0.05);SD组不良反应发生率明显低于PR组(P<0.05)。结论 SOF联合DCV方案可有效改善慢性丙型肝炎患者肝功能,降低不良反应。

Objective To observe the clinical efficacy of sofosbuvir（SOF） and daclatasvir（DCV） for chronic hepatitis C（CHC）. A total of 100 CHC cases were randomized to SD（Methods n=40） and PR（n=60） groups, and respectively treated with SOF plus DCV and pegylated interferon plus ribavirin. Liver function, HCV-RNA negative rate, virological response rate and adverse reactions were observed after therapy. ResultsThe incidence of alanine aminotransferase（ALT）, aspartate aminotransferase（AST） and total bilirubin（TBIL） abnormality was decreased in 2 groups after 48-week treatment, especially in SD group（P〈0.05）. The negative rate of non-type Ⅰ HCV-RNA was higher in SD group than in PR group after 12-week treatment（P〈0.05）. The incidence of adverse reactions was lower in SD group than in PR group（P〈0.05）. Conclusion Combined use of SOF and DCV can improve the liver function and reduce the adverse reactions in patients with CHC.